|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1098.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 15,718.74 | 23,374.46 | 19,437.57 | 15,346.44 | 20,210.18 | Adjustment | 1,224.75 | -6,174.96 | 2,351.11 | -1,071.84 | -3,547.50 | Changes In working Capital | 1,961.33 | -1,131.67 | -5,996.12 | 4,910.05 | 12,217.80 | Cash Flow after changes in Working Capital | 18,904.82 | 16,067.83 | 15,792.56 | 19,184.65 | 28,880.48 | Cash Flow from Operating Activities | 14,740.63 | 12,160.67 | 12,434.17 | 15,791.18 | 24,895.83 | Cash Flow from Investing Activities | -4,314.67 | -8,969.20 | -12,352.30 | -16,073.83 | -22,556.05 | Cash Flow from Financing Activities | -9,784.98 | -3,051.20 | -807.94 | -1,394.16 | -1,551.06 | Net Cash Inflow / Outflow | 640.98 | 140.27 | -726.07 | -1,676.81 | 788.72 | Opening Cash & Cash Equivalents | 286.50 | 147.23 | 872.92 | 2,549.97 | 1,760.47 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 0 | -0.81 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | -0.52 | -1.00 | 0.38 | -0.24 | 1.59 | Closing Cash & Cash Equivalent | 926.96 | 286.50 | 147.23 | 872.92 | 2,549.97 |
|
|
|
|
|
|